Innate Pharma has recently announced phase 2 of a clinical trial dubbed TELLOMAK regarding the investigative drug lacutamab (IPH4102), an anti-KIR3DL2 monoclonal antibody, alone or in combination with chemo. The focus of this study is the treatment of patients with the rare cutaneous t-cell lymphoma (CTCL) Mycosis Fungoides and it’s systemic comparable Sézary Syndrome.
The Cutaneous Lymphoma Foundation recently held an online discussion with Dr. Joyson Karakunnel, Executive VP, Chief Medical Officer at Innate Pharma and Dr. Youn Kim, Professor, Director of the Multidisciplinary Cutaneous Lymphoma Program at Stanford Cancer Center, regarding the trial. Click this LINK to watch a recording of the session
TELLOMAK is under way at 35 locations across the U.S. and internationally. More information regarding the trial, including participation criteria, is available at Clinicaltrials.gov where the trial is labeled NCT03902184.
AGSchreibman.com 